ResMed Inc. (RMD) News

ResMed Inc. (RMD): $237.34

0.71 (+0.30%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter RMD News Items

RMD News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

RMD News Highlights

  • For RMD, its 30 day story count is now at 25.
  • Over the past 19 days, the trend for RMD's stories per day has been choppy and unclear. It has oscillated between 1 and 10.
  • The most mentioned tickers in articles about RMD are ASX, MA and API.

Latest RMD News From Around the Web

Below are the latest news stories about Resmed Inc that investors may wish to consider to help them evaluate RMD as an investment opportunity.

3 Beaten-Down Growth Stocks With More Than 50% Upside Potential

The key to picking growth stocks right now is to look for companies whose earnings momentum and growth can withstand any market conditions.

Jaimini Desai on InvestorPlace | February 25, 2022

ResMed Inc. Consensus Indicates Potential 14.4% Upside

ResMed Inc. found using ticker (RMD) have now 5 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 312 and 235 calculating the mean target price we have 268. With the stocks previous close at 234.24 this is indicating there is a potential upside of 14.4%. There is a 50 day moving average of 245.2 while the 200 day moving average is 252.14. The market cap for the company is $33,887m. You can visit the company''s website by visiting: https://www.resmed.com [stock_market_widget type="chart" template="basic" color="green" assets=RMD" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $38,771m based on the market concensus. ResMed Inc. develops, man...

DirectorsTalk | February 20, 2022

ResMed Announces Participation in the Citi Healthcare Conference

SAN DIEGO, Feb. 16, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer, will participate in a virtual fireside chat at the Citi Healthcare Conference on Wednesday, February 23, 2022, beginning at approximately 12:30 p.m. (Eastern Standard Time) via webcast.

GlobeNewswire | February 16, 2022

ResMed Inc. Consensus Indicates Potential 9.7% Upside

ResMed Inc. with ticker code (RMD) have now 5 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The range between the high target price and low target price is between 312 and 235 and has a mean target at 268. With the stocks previous close at 244.35 this is indicating there is a potential upside of 9.7%. The day 50 moving average is 247.85 and the 200 day MA is 251.08. The company has a market capitalisation of $35,669m. You can visit the company''s website by visiting: https://www.resmed.com [stock_market_widget type="chart" symbol="RMD" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] The potential market cap would be $39,122m based on the market concensus. ResMed Inc. develops, manufactures, distributes, and markets medical device...

DirectorsTalk | February 13, 2022

ResMed declares go ex dividend tomorrow

No summary available.

Seeking Alpha | February 8, 2022

CCLA Investment Management Ltd Buys PepsiCo Inc, PayPal Holdings Inc, Brookfield Renewable ...

Investment company CCLA Investment Management Ltd (Current Portfolio) buys PepsiCo Inc, PayPal Holdings Inc, Brookfield Renewable Partners LP, Zoetis Inc, The Walt Disney Co, sells Activision Blizzard Inc, Blackstone Inc, NVIDIA Corp, Synopsys Inc, Masco Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, CCLA Investment Management Ltd.

Yahoo | February 8, 2022

Here's Why You Should Hold on to ResMed (RMD) Stock for Now

Investors are optimistic about ResMed (RMD) on increased demand for sleep and respiratory care devices on steady recovery of markets from COVID-19 impacts.

Yahoo | February 8, 2022

Harfst & Associates, Inc. Buys Cummins Inc, Raytheon Technologies Corp, ResMed Inc, Sells ...

Investment company Harfst & Associates, Inc. (Current Portfolio) buys Cummins Inc, Raytheon Technologies Corp, ResMed Inc, Air Products & Chemicals Inc, Texas Instruments Inc, sells ARK Innovation ETF, Activision Blizzard Inc, Hormel Foods Corp, Invesco BulletShares 2021 Corporate Bond ETF, Intel Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Harfst & Associates, Inc..

Yahoo | February 8, 2022

Synergy Asset Management, LLC Buys Johnson & Johnson, Global Payments Inc, Ross Stores Inc, ...

Investment company Synergy Asset Management, LLC (Current Portfolio) buys Johnson & Johnson, Global Payments Inc, Ross Stores Inc, ResMed Inc, Costco Wholesale Corp, sells SPDR Bloomberg 1-3 Month T-Bill ETF, Apple Inc, Amazon.com Inc, Ashland Global Holdings Inc, ProShares Short 20+ Year Treasury during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Synergy Asset Management, LLC.

Yahoo | February 5, 2022

ResMed Welcomes Urvashi Tyagi as New Chief Technology Officer

Urvashi Tyagi, ResMed Chief Technology Officer Urvashi Tyagi, ResMed Chief Technology Officer Tyagi brings over 25 years’ IT and leadership experience from ADP, American Express, Amazon, Microsoft, and IBMCurrent CTO and SaaS President Bobby Ghoshal now transitions to SaaS full-time SAN DIEGO, Feb. 01, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced the appointment of Urvashi Tyagi as chief technology officer (CTO), effective today. As CTO, Tyagi will lead ResMed’s Digital

Yahoo | February 1, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6142 seconds.